Affiliation:
1. School of Medicine Wayne State University Detroit Michigan USA
2. Department of Oncology School of Medicine Detroit Michigan USA
3. Population Sciences and Disparities Research Program Karmanos Cancer Institute Detroit Michigan USA
4. Indiana University Simon Comprehensive Cancer Center Indianapolis Indiana USA
Abstract
AbstractBackgroundThe use of electronic cigarettes (e‐cigarettes) is increasing rapidly in the United States, although the negative health outcomes associated with these products are still unknown. Emerging research has examined the use of e‐cigarettes in the cancer survivor population as a whole, yet none has focused on e‐cigarette use in the African American (AA) cancer survivor population.MethodsThe authors used data from the Detroit Research on Cancer Survivors cohort study, comprised of AA adult cancer survivors. Logistic regression models were used to evaluate factors potentially associated with e‐cigarette ever use and current use.ResultsOf 4443 cancer survivors who completed a baseline interview, 8.3% (n = 370) reported ever using e‐cigarettes, and 16.5% (n = 61) of those reporting ever use also reported current use of e‐cigarettes. Ever users and current users were on average younger than those who did not use e‐cigarettes (57.5 vs. 61.2 years; p < .001). Current cigarette smokers were >20 times more likely (odds ratio, 20.75; 95% confidence interval, 12.84–33.55) and former smokers were almost 10 times more likely (odds ratio, 9.50; 95% confidence interval, 6.03–14.97) to have ever used e‐cigarettes than never‐smokers. Preliminary data suggested that ever use of e‐cigarettes is associated with later stage at diagnosis for breast and colorectal cancers.ConclusionsAs the use of e‐cigarettes increases in the general population, it is important to continue to monitor their use in cancer survivors and to gain more insight as it pertains to the AA cancer survivor population. Elucidation of the factors associated with e‐cigarette use in this population may help inform comprehensive cancer survivorship recommendations and interventions.